Prescribed Medications for Acute Treatment of Migraine Market Industry Share, Size, Growth 2022-2028

According to Precision Business Insights (PBI) latest report the prescribed medications for acute treatment of migraine market worth USD 2,587.9million in 2022, growing at a 13.7% CAGR from 2022 to 2028. The global prescribed medications for acute treatment of migraine market segmented into following types: By Drug Type (Abortive and Prophylactic), By Route of Administration (Oral, Injectables, and Others) By Distribution Channel (Hospital Pharmacies, Retail pharmacies, and Online Pharmacies) and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa) Forecast to 2028. Key player's profiles in the prescribed medications for acute treatment of migraine market report are Biohaven Pharmaceuticals, Merck & Co., Inc., Pfizer Inc., Astrazeneca, Eli Lilly and Company, Avanir Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Allergan. The market for prescribed medications for acute treatment of migraine is expected to offer lucrative opportunities for the market players due to the launch of novel molecules in the U.S. market. The companies have focused on novel therapeutics, an alternative to the triptan class of drugs due to the adverse effects like cardiovascular disorders, chest pressure, and others. Novel treatment options and increased prevalence of migraine are expected to drive the market. Increased awareness initiatives, the availability of research funds from private and public bodies, a development in the reimbursement scenario for associated medications, and increasing awareness about the effectiveness of such medicines are among the significant factors fuelling the market's growth. Furthermore, rising pharmaceutical R&D operating costs and rising healthcare spending are expected to drive the global prescribed medications for acute migraine treatment market growth rate during the forecast period.

View Detailed Report Description Here - https://precisionbusinessinsights.com/market-reports/global-prescribed-medication-for-acute-treatment-for-migrane-market

Abortive prescribed medications segment Dominates the Prescribed Medications for Acute Treatment of Migraine Market:
In the prescribed medications for acute treatment of migraine market, abortive prescribed medications for acute treatment of migraine accounted for a larger revenue share in 2021 and are projected to grow with a CAGR of X% from 2020-2026 to reach US$ X Mn by 2026. However, the market for prophylactic drugs is anticipated to grow with a significant CAGR over the forecast years in prescribed medications for acute treatment of migraine. The increasing awareness of novel drug classes and the rising incidence of migraine problems worldwide drive the target market's growth. Additionally, factors such as increasing work pressure, high alcohol consumption, growing demand for quality drugs, changes in lifestyles, and awareness among patients associated with the prevention and treatment of migraine further increase the demand levels for the global prescribed medications for acute treatment of migraine market. The increasing precedence of other therapies and side effects associated with migraine drugs limit the growth of the Prescribed Medications for Acute Migraine Treatment Market.

North America Leads Prescribed Medications for Acute Treatment of Migraine Market:
North America Prescribed Medications for Acute Treatment of Migraine market held the highest market share of 60.8% in 2021. Favorable reimbursements for migraine medications, a growing emphasis on precision medicine, increased awareness about various migraine medications, and well-established market players in the region are among the key factors driving the market growth for prescribed medications for acute migraine treatment in this region. In addition, Europe will be the second-largest shareholder owing to the high development of generic drugs is available at a low cost and the subsequent support from governments across several countries for these drugs.

Strategic New Product Launches, Mergers, Acquisitions and Agreements are the key strategies adopted by market players:
Global The Prescribed Medications for Acute Treatment of Migraine Market further reveals that the key players increasingly adopting strategies such as launch of newer products, product launches, and long-term alliance to improve market revenue share and gaining significant geographic presence across the region. For instance, In February 2022, Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. It is recommended as the 75 mg dose of Rimegepant (available as an orally dissolving tablet) for marketing authorization for both the acute treatment of migraine with or without aura in adults and the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month.

Request sample report at https://precisionbusinessinsights.com/request-sample?product_id=40858

Detailed Segmentation
Based on the Drug Type, the market is segmented into the following:
• Abortive
• Prophylactic

Based on the Route of Administration, the market is segmented into the following:
• Oral
• Injectables
• Others.

Based on the Distribution Channel, the market is segmented into the following:
• Hospital Pharmacies
• Retail pharmacies
• Online Pharmacies

Based on the geography, the market is segmented into the following:
• North America
• Europe
• Asia Pacific
• Latin America
• MEA

Contact:
Mr. Satya
Precision Business InsightsTM | Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 - 160 City Road, London EC1V 2NX
Web: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

This release was published on openPR.